HC Wainwright Estimates Alphatec’s Q3 Earnings (NASDAQ:ATEC)

Posted by George Bondi on Aug 12th, 2026

Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) – Stock analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for Alphatec in a report released on Wednesday, August 5th. HC Wainwright analyst S. Lee now expects that the medical technology company will earn ($0.02) per share for the quarter, up from their previous estimate of ($0.06). HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Alphatec’s Q4 2026 earnings at $0.07 EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.11 EPS, Q4 2027 earnings at $0.18 EPS, FY2028 earnings at $0.79 EPS and FY2029 earnings at $1.05 EPS.

Other research analysts have also issued research reports about the stock. Stephens began coverage on shares of Alphatec in a research note on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on shares of Alphatec from $24.00 to $16.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Barclays reduced their price target on shares of Alphatec from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. TD Cowen boosted their price target on shares of Alphatec from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Lake Street Capital restated a “buy” rating and issued a $15.00 price objective on shares of Alphatec in a research report on Wednesday, May 6th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.40.

View Our Latest Stock Analysis on ATEC

Alphatec Stock Performance

Shares of ATEC stock opened at $9.37 on Wednesday. The stock has a market cap of $1.45 billion, a PE ratio of -13.20 and a beta of 0.85. The stock has a 50-day moving average of $8.87 and a 200-day moving average of $10.55. The company has a debt-to-equity ratio of 40.35, a current ratio of 1.89 and a quick ratio of 1.07. Alphatec has a one year low of $6.82 and a one year high of $23.29.

Alphatec (NASDAQ:ATEC – Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. The firm had revenue of $213.51 million for the quarter, compared to analysts’ expectations of $211.26 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 13.49%.The company’s revenue was up 15.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.02 earnings per share.

Institutional Investors Weigh In On Alphatec

Several large investors have recently made changes to their positions in ATEC. Creative Planning raised its stake in shares of Alphatec by 0.9% during the 3rd quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock worth $853,000 after purchasing an additional 534 shares in the last quarter. Great Lakes Advisors LLC grew its stake in shares of Alphatec by 0.4% in the fourth quarter. Great Lakes Advisors LLC now owns 278,717 shares of the medical technology company’s stock valued at $5,864,000 after buying an additional 1,226 shares in the last quarter. Franklin Resources Inc. increased its holdings in Alphatec by 2.0% during the fourth quarter. Franklin Resources Inc. now owns 64,774 shares of the medical technology company’s stock worth $1,363,000 after buying an additional 1,299 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Alphatec by 9.9% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 15,075 shares of the medical technology company’s stock worth $317,000 after buying an additional 1,353 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in Alphatec by 157.1% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock worth $54,000 after acquiring an additional 1,571 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Insider Activity

In related news, Director Karen K. Mcginnis sold 6,050 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $8.01, for a total transaction of $48,460.50. Following the completion of the sale, the director directly owned 94,671 shares of the company’s stock, valued at approximately $758,314.71. This represents a 6.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Tyson Eliot Marshall sold 8,168 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total transaction of $78,821.20. Following the sale, the general counsel owned 630,398 shares in the company, valued at $6,083,340.70. This trade represents a 1.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 13.48% of the company’s stock.

More Alphatec News

Here are the key news stories impacting Alphatec this week:

Positive Sentiment: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.02 from a loss of $0.06 and increased its Q4 2026 estimate to $0.07 from $0.05. These revisions suggest better-than-expected near-term operating performance and could support the stock.
Positive Sentiment: The analyst projects Alphatec will become profitable in 2027, with quarterly EPS estimates ranging from $0.08 to $0.18, followed by earnings of $0.79 per share in 2028 and $1.05 in 2029. The FY2029 forecast was raised from $1.00, reinforcing the longer-term earnings-growth case.
Positive Sentiment: The $24 price target represents a significant premium to the stock’s recent trading level. Investors may view the target and continued Buy rating as evidence that HC Wainwright sees meaningful value in Alphatec’s medical-technology platform and path toward profitability.
Neutral Sentiment: Alphatec’s latest reported quarter was solid, with revenue of $213.5 million, up 15.1% year over year and above analyst expectations, while EPS matched the $0.07 consensus estimate. However, the company remains unprofitable overall, with analysts expecting a full-year loss of $0.44 per share.
Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a loss of $0.29 from a loss of $0.28, lowered FY2027 EPS to $0.47 from $0.59, and cut FY2028 EPS to $0.79 from $0.88. These reductions indicate that the profitability ramp may be slower than previously expected.
Negative Sentiment: The reported short-interest data shows zero shares and a zero-day days-to-cover ratio, but the figures appear unreliable and provide no meaningful indication of short-seller positioning.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.